Christian P Selinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8149494/publications.pdf

Version: 2024-02-01

162 papers 5,687 citations

33 h-index 71 g-index

164 all docs

164 docs citations

times ranked

164

5797 citing authors

#	Article	IF	CITATIONS
1	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68, s1-s106.	12.1	1,353
2	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
3	The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2015, 9, 107-124.	1.3	369
4	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
5	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2020, 69, 984-990.	12.1	232
6	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153
7	Inflammatory bowel disease and pregnancy: Lack of knowledge is associated with negative views. Journal of Crohn's and Colitis, 2013, 7, e206-e213.	1.3	146
8	Gastric Antral Vascular Ectasia (GAVE): An Update on Clinical Presentation, Pathophysiology and Treatment. Digestion, 2008, 77, 131-137.	2.3	136
9	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. The Lancet Gastroenterology and Hepatology, 2018, 3, 671-680.	8.1	126
10	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. The Lancet Gastroenterology and Hepatology, 2021, 6, 218-224.	8.1	111
11	Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 117-131.	8.1	108
12	Modifiable Factors Associated with Nonadherence to Maintenance Medication for Inflammatory Bowel Diseases, 2013, 19, 2199-2206.	1.9	102
13	Medication adherence in inflammatory bowel disease. Intestinal Research, 2017, 15, 434.	2.6	102
14	Patients' knowledge of pregnancyâ€related issues in inflammatory bowel disease and validation of a novel assessment tool (<scp>CCPKnow</scp> '). Alimentary Pharmacology and Therapeutics, 2012, 36, 57-63.	3.7	81
15	Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2015, 42, 61-70.	3.7	81
16	Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. Journal of Hospital Infection, 2013, 84, 159-165.	2.9	78
17	What Factors Might Drive Voluntary Childlessness (VC) in Women with IBD? Does IBD-specific Pregnancy-related Knowledge Matter?. Journal of Crohn's and Colitis, 2016, 10, 1151-1158.	1.3	77
18	Inflammatory bowel disease and anxiety: links, risks, and challenges faced. Clinical and Experimental Gastroenterology, 2015, 8, 111.	2.3	76

#	Article	IF	CITATIONS
19	Long-term Follow-up Reveals Low Incidence of Colorectal Cancer, but Frequent Need for Resection, Among Australian Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 644-650.	4.4	74
20	A multiâ€centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 964-973.	3.7	62
21	Better disease specific patient knowledge is associated with greater anxiety in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, e214-e218.	1.3	54
22	Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opinion on Drug Safety, 2011, 10, 863-870.	2.4	52
23	Early Use of Thiopurines or Methotrexate Reduces Major Abdominal and Perianal Surgery in Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 1382-1390.	1.9	48
24	The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 1316-1329.	1.3	48
25	A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. Digestive and Liver Disease, 2018, 50, 1299-1304.	0.9	44
26	Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants. Infection Control and Hospital Epidemiology, 2018, 39, 771-781.	1.8	42
27	Pregnancy related issues in inflammatory bowel disease: Evidence base and patients' perspective. World Journal of Gastroenterology, 2012, 18, 2600.	3.3	41
28	Mortality from Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2012, 18, 1566-1572.	1.9	39
29	Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Review of Gastroenterology and Hepatology, 2017, 11 , 1 - 12 .	3.0	39
30	Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease. Journal of Crohn's and Colitis, 2019, 13, 693-701.	1.3	39
31	Assessment of steroid use as a key performance indicator in inflammatory bowel diseaseâ€"analysis of data from 2385 UK patients. Alimentary Pharmacology and Therapeutics, 2019, 50, 1009-1018.	3.7	37
32	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterology, 2020, 11, 343-350.	1.8	37
33	A good death certificate: improved performance by simple educational measures. Postgraduate Medical Journal, 2007, 83, 285-286.	1.8	36
34	Cause-Specific Mortality and 30-year Relative Survival of Crohn $\hat{E}\frac{1}{4}$ s Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1.	1.9	36
35	The relationship between different information sources and diseaseâ€related patient knowledge and anxiety in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 63-74.	3.7	36
36	Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scandinavian Journal of Gastroenterology, 2018, 53, 700-707.	1.5	35

#	Article	IF	Citations
37	Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohnʽs Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 1257-1261.	1.9	33
38	Long-term success of colonic stent insertion is influenced by indication but not by length of stent or site of obstruction. International Journal of Colorectal Disease, 2011, 26, 215-218.	2.2	30
39	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	12.1	28
40	Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. World Journal of Hepatology, 2012, 4, 43.	2.0	28
41	Knowledge and Attitudes Towards Pregnancy in Females with Inflammatory Bowel Disease: An International, Multi-centre Study. Journal of Crohn's and Colitis, 2020, 14, 1248-1255.	1.3	27
42	IBD in pregnancy: recent advances, practical management. Frontline Gastroenterology, 2021, 12, 214-224.	1.8	27
43	Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients′ reproductive health. Alimentary Pharmacology and Therapeutics, 2018, 48, 1202-1212.	3.7	26
44	Stigmatisation and resilience in inflammatory bowel disease. Internal and Emergency Medicine, 2020, 15, 211-223.	2.0	26
45	Standards for the provision of antenatal care for patients with inflammatory bowel disease: guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society. Frontline Gastroenterology, 2021, 12, 182-187.	1.8	26
46	Oesophageal stent insertion for palliation of dysphagia in a District General Hospital: experience from a case series of 137 patients. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 545-548.	0.5	24
47	The role of multimodal treatment in Crohn′s disease patients with perianal fistula: a multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2018, 48, 941-950.	3.7	24
48	Pregnancy and inflammatory bowel disease: Do we provide enough patient education? A British study of 1324 women. World Journal of Gastroenterology, 2016, 22, 8219.	3.3	24
49	Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immuneâ€mediated inflammatory diseases: A European retrospective observational study. United European Gastroenterology Journal, 2021, 9, 1136-1147.	3.8	24
50	Inflammatory bowel diseaseâ€specific pregnancy knowledge of gastroenterologists against general practitioners and obstetricians. United European Gastroenterology Journal, 2015, 3, 462-470.	3.8	23
51	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281.	8.1	23
52	Managing inflammatory bowel disease in pregnancy: current perspectives. Clinical and Experimental Gastroenterology, 2016, Volume 9, 325-335.	2.3	22
53	The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios. Inflammatory Bowel Diseases, 2019, 25, 919-924.	1.9	19
54	Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1774473.	3.2	18

#	Article	IF	CITATIONS
55	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 304-313.	1.9	17
56	A propensity scoreâ€matched, realâ€world comparison of ustekinumab vs vedolizumab as a secondâ€line treatment for Crohn's disease. The Cross Pennine study II. Alimentary Pharmacology and Therapeutics, 2022, 55, 856-866.	3.7	17
57	Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1390-1398.	1.9	16
58	Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 2083-2088.	1.9	15
59	Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1091-1096.	3.0	15
60	Gastric ulcers: malignancy yield and risk stratification for follow-up endoscopy. Endoscopy International Open, 2016, 04, E709-E714.	1.8	13
61	Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. Frontline Gastroenterology, 2017, 8, 203-209.	1.8	13
62	Lived experience in people with inflammatory bowel disease and comorbid anxiety and depression in the United Kingdom and Australia. Journal of Health Psychology, 2021, 26, 2290-2303.	2.3	13
63	When to use biological agents in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1141-1149.	2.8	12
64	Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 987-988.	8.1	12
65	Inflammatory bowel disease patientâ€reported quality assessment should drive service improvement: a national survey of <scp>UK IBD </scp> units and patients. Alimentary Pharmacology and Therapeutics, 2022, 56, 625-645.	3.7	12
66	Current smoking habits in British IBD patients in the age of e-cigarettes. BMJ Open Gastroenterology, 2019, 6, e000309.	2.7	11
67	Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterology, 2021, 12, 207-213.	1.8	11
68	Adherence to BSG adenoma surveillance guidelines will reduce colonoscopic workload. Gut, 2005, 54, 173-173.	12.1	10
69	Fracture of an esophageal stent: a rare but significant complication. Endoscopy, 2008, 40, E199-E199.	1.8	10
70	Is gastrointestinal endoscopy a risk factor for Clostridium difficile associated diarrhea?. American Journal of Infection Control, 2010, 38, 581-582.	2.3	10
71	Patients' Beliefs and Concerns About the Necessity of Long-Term Therapies Are Crucial for Medication Adherence for Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2017, 11, jjw213.	1.3	10
72	Predicting COVID-19 incidence in French hospitals using human contact network analytics. International Journal of Infectious Diseases, 2021, 111, 100-107.	3.3	9

#	Article	IF	CITATIONS
73	When Your Pregnancy Echoes Your Illness: Transition to Motherhood With Inflammatory Bowel Disease. Qualitative Health Research, 2018, 28, 1283-1294.	2.1	8
74	Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD. BMJ Open Gastroenterology, 2021, 8, e000603.	2.7	8
75	The cost–effectiveness of infliximab in Crohn's disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 589-598.	1.4	7
76	Acceptability of a â€~treat to target' approach in inflammatory bowel disease to patients in clinical remission. Frontline Gastroenterology, 2021, 12, 30-38.	1.8	7
77	Current practice and clinicians' perception of medication non-adherence in patients with inflammatory bowel disease: A survey of 98 clinicians. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2017, 8, 67.	1.1	7
78	OTU-003â€Etrolizumab as induction therapy in moderate to severe crohn's disease: results from bergamot cohort 1., 2018, , .		6
79	Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2021, 33, 1524-1532.	1.6	6
80	Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. Neurogastroenterology and Motility, 2022, 34, e14256.	3.0	6
81	The role of biologics in the treatment of patients with inflammatory bowel disease. British Journal of Hospital Medicine (London, England: 2005), 2018, 79, 686-693.	0.5	5
82	Patients' perception of colonoscopy and acceptance of colonoscopy based IBD related colorectal cancer surveillance. Expert Review of Gastroenterology and Hepatology, 2021, 15, 211-216.	3.0	5
83	Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Internal and Emergency Medicine, 2021, 16, 1433-1442.	2.0	5
84	Optimizing the early detection of low pathogenic avian influenza H7N9 virus in live bird markets. Journal of the Royal Society Interface, 2021, 18, 20210074.	3.4	5
85	Perineal Outcomes After Delivery in 179 Mothers with Inflammatory Bowel Disease Compared to 31 258 Controls: A Single-Centre Cohort Study. Journal of Crohn's and Colitis, 2021, , .	1.3	5
86	Provision of care for pregnant women with IBD in the UK: the current landscape. Frontline Gastroenterology, 2021, 12, 487-492.	1.8	5
87	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. Gut, 2023, 72, 410-412.	12.1	5
88	Risk of Adverse Pregnancy Outcomes for Women with IBD in an Expert IBD Antenatal Clinic. Journal of Clinical Medicine, 2022, 11, 2919.	2.4	5
89	Understanding <scp>antiâ€TNF</scp> treatment failure: does serum triiodothyronineâ€toâ€thyroxine (<scp>T3</scp> / <scp>T4</scp> therapies in biologicâ€na¯ve patients with active luminal Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2022, 56, 783-793.	3.7	5
90	Helicobacter pylori Eradication in Diabetic Patients: Still Far Off the Treatment Targets. Southern Medical Journal, 2010, 103, 975-976.	0.7	4

#	Article	IF	Citations
91	Preferable Colonic Investigations for Isolated Abdominal Pain. Southern Medical Journal, 2011, 104, 170-173.	0.7	4
92	Conveying medication benefits to ulcerative colitis patients and effects on patient attitudes regarding thresholds for adherence. Journal of Crohn's and Colitis, 2013, 7, e312-e317.	1.3	4
93	Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. Expert Review of Gastroenterology and Hepatology, 2014, 8, 329-334.	3.0	4
94	Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderateto-Severe Crohn's Disease. Gastroenterology, 2017, 152, S1310.	1.3	4
95	Letter: increased risk of caesarean section for women with IBD—more questions than answers. Alimentary Pharmacology and Therapeutics, 2020, 51, 667-668.	3.7	4
96	Reproduction in the patient with inflammatory bowel disease. Minerva Gastroenterologica E Dietologica, 2013, 59, 285-97.	2.2	4
97	Managing Inflammatory Bowel Disease in Pregnancy: Health Care Professionals' Involvement, Knowledge, and Decision Making. Inflammatory Bowel Diseases, 2023, 29, 522-530.	1.9	4
98	Flexible Sigmoidoscopy Does Not Significantly Increase Polyp and Cancer Detection Yield when Used to Supplement CT Colonography. Digestion, 2012, 85, 55-60.	2.3	3
99	The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment. Inflammatory Intestinal Diseases, 2020, 5, 191-199.	1.9	3
100	Screening for TB in Hospitalised Patients with Inflammatory Bowel Disease before Anti-TNF Therapy: Is QuantiFERON® Gold Testing Useful?. Journal of Clinical Medicine, 2021, 10, 1816.	2.4	3
101	Gastric Cancer in Patients with Inflammatory Bowel Disease: More than just a Random Association?. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 11-12.	0.9	3
102	Gastroenterology team members' knowledge and practices with fertility therapy for women with inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210875.	3.2	3
103	Using the PIDA on Your PDA: Providing Personalized Education and Decision Support for Women with IBD of Childbearing Age. Digestive Diseases and Sciences, 2022, 67, 4315-4316.	2.3	3
104	The source of individual heterogeneity shapes infectious disease outbreaks. Proceedings of the Royal Society B: Biological Sciences, 2022, 289, 20220232.	2.6	3
105	Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds <scp>IBD</scp> Steroids study. Alimentary Pharmacology and Therapeutics, 0, , .	3.7	3
106	Tablet induced dysphagia in oesophageal cancer. Gut, 2006, 55, 587-588.	12.1	2
107	Coffee ground vomit is difficult to identify. European Journal of Gastroenterology and Hepatology, 2007, 19, 825.	1.6	2
108	Eosinophilic gastritis with idiopathic thrombocytopaenic purpura: coincidence or association?. European Journal of Gastroenterology and Hepatology, 2009, 21, 1425-1427.	1.6	2

#	Article	IF	Citations
109	Commentary: 5-ASA switches in IBD, adherence and flares. Alimentary Pharmacology and Therapeutics, 2013, 38, 1138-1138.	3.7	2
110	How costly is non-adherence to infliximab in patients with Crohn's disease?. Journal of Medical Economics, 2014, 17, 881-882.	2.1	2
111	Adapting †Tame Your Gut†for patients with inflammatory bowel disease and co-morbid anxiety and/or depression. Journal of Health Psychology, 2022, 27, 58-68.	2.3	2
112	Letter: recognising frailty in patients with inflammatory bowel disease is crucial for appropriate personalised treatment. Alimentary Pharmacology and Therapeutics, 2020, 52, 908-909.	3.7	2
113	Utility of Fecal Calprotectin in Routine Clinical Practice Is Impaired by Poor Sample Return Rates. Digestive Diseases and Sciences, 2021, 66, 3209-3210.	2.3	2
114	Biologicals are the main contributor to cost of care for IBD: a European perspective. The Lancet Gastroenterology and Hepatology, 2020, 5, 421-422.	8.1	2
115	Letter: pregnant women with IBD are more likely to be adherent to biologic therapies than other medications. Alimentary Pharmacology and Therapeutics, 2020, 51, 915-916.	3.7	2
116	Risk stratifying gastric ulcers: development and validation of a scoring system. Frontline Gastroenterology, 2022, 13, flgastro-2020-101759.	1.8	2
117	Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterology, 2022, 13, 77-81.	1.8	2
118	Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. Journal of Clinical Medicine, 2021, 10, 4329.	2.4	2
119	Episome partitioning and symmetric cell divisions: Quantifying the role of random events in the persistence of HPV infections. PLoS Computational Biology, 2021, 17, e1009352.	3.2	2
120	Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterology, 2022, 13, 490-496.	1.8	2
121	An unusual inflammation of the colon. Gut, 2010, 59, 1393-1393.	12.1	1
122	205 Intestinal Barrier Dysfunction Measured With Confocal Endomicroscopy in Macroscopically Normal Mucosa Can Predict Requirement for Treatment Escalation. Gastrointestinal Endoscopy, 2013, 77, AB136.	1.0	1
123	Gastrointestinal: Cause or effect: A case of microcytic anemia. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1793-1793.	2.8	1
124	Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. Rheumatology, 2021, 60, 467-470.	1.9	1
125	Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA. Expert Opinion on Biological Therapy, 2021, 21, 111-119.	3.1	1
126	A †real†world†metrospective multi†centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis. Gastro Hep, 2021, 3, 229-235.	0.6	1

#	Article	IF	Citations
127	Reconstructing contact network structure and cross-immunity patterns from multiple infection histories. PLoS Computational Biology, 2021, 17, e1009375.	3.2	1
128	Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. Inflammatory Intestinal Diseases, 2021, 6, 132-139.	1.9	1
129	The economics of biological therapy for inflammatory bowel disease and the case for equality. Polish Archives of Internal Medicine, 2017, 127, 650-651.	0.4	1
130	Evaluation of Anorectal Function in Perianal Crohn's Disease: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 5909.	2.4	1
131	Editorial: can serum triiodothyronineâ€toâ€thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?. Alimentary Pharmacology and Therapeutics, 2021, 53, 346-347.	3.7	1
132	Editorial: standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps but a first step in the right direction. Alimentary Pharmacology and Therapeutics, 2021, 53, 1147-1148.	3.7	1
133	Editorial: choosing the optimal screening method for latent <scp>TB</scp> in patients with <scp>IBD</scp> commencing <scp>antiâ€₹NF</scp> therapy. Alimentary Pharmacology and Therapeutics, 2022, 55, 1346-1347.	3.7	1
134	Endoscopic Clearance of Common Bile Duct Stones: What Happens After? Value of Prophylactic Cholecystectomy. Gastrointestinal Endoscopy, 2008, 67, AB164-AB165.	1.0	0
135	T2063 Is Gastrointestinal Endoscopy a Risk Factor for Clostridium difficile Associated Diarrhoea?. Gastroenterology, 2009, 136, A-631.	1.3	0
136	PTH-014â€Does flexible sigmoidoscopy increase the polyp and cancer detection yield when used to supplement CT colonography?. Gut, 2010, 59, A128.1-A128.	12.1	0
137	T1223 Does Flexible Sigmoidoscopy Increase the Polyp and Cancer Detection Yield When Used to Supplement CT Colonography?. Gastroenterology, 2010, 138, S-515.	1.3	0
138	W1472: Colonic Investigations for Isolated Abdominal Pain: Endoscopy or CT Colonography?. Gastrointestinal Endoscopy, 2010, 71, AB337.	1.0	0
139	W1473: Colonic Stents: Which Factors Influence Technical and Clinical Success?. Gastrointestinal Endoscopy, 2010, 71, AB337.	1.0	0
140	Mo1637 Confocal Endomicroscopy Identifies Intestinal Mucosal Barrier Dysfunction in Macroscopically-Normal Crohn's Disease and Ulcerative Colitis. Gastrointestinal Endoscopy, 2013, 77, AB454.	1.0	0
141	Cancer surveillance for patients with colonic Crohn's disease: will your patients benefit?. Journal of Crohn's and Colitis, 2013, 7, e714.	1.3	0
142	One size fits all? Choosing the right format to convey statistical information. Journal of Crohn's and Colitis, 2014, 8, 1565.	1.3	0
143	Mo1842 Excess Steroid Use in IBD: Too Much, How Much and Why? Results From a UK Nationwide Audit. Gastroenterology, 2016, 150, S791.	1.3	О
144	SEMS for Palliation of Malignant Colonic Obstruction: Why SEMi Available Is Not Good Enough. Digestive Diseases and Sciences, 2016, 61, 1781-1782.	2.3	0

#	Article	IF	CITATIONS
145	Female Gender, Somatization and Presence of IBS-Type Symptoms Predicts Dyspareunia in Patients with IBD. Gastroenterology, 2017, 152, S795.	1.3	0
146	Presentation and Surgical Interventions for Crohn's Disease with Perianal Fistula in the Biologics Era: Results from a Multicentre Study. Gastroenterology, 2017, 152, S1282.	1.3	0
147	Multicentre Cohort Study to Evaluate the Need for Re-Intervention following Multimodal Treatment in Croh <mml:math altimg="si1.gif" overflow="scroll" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mover><mml:mtext>n</mml:mtext><mml:mo></mml:mo></mml:mover></mml:math> s Disease with Perianal Fistula, Gastroenterology, 2017, 152, S778.	1.3	O
148	Editorial: avoiding corticosteroids in the treatment of inflammatory bowel diseaseâ€"Author's reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 145-145.	3.7	0
149	ADTU-03â€Impact of improved access to biologic therapies and physician engagement on excess steroid exposure. , 2018, , .		O
150	ADTU-06â€â€real world' outcomes of vedolizumab over 12 months: the cross pennine multicentre experience. , 2018, , .		0
151	PTU-007â€A retrospective multicentre study comparing infliximab and adalimumab for maintenance of remission in ulcerative colitis. , 2018, , .		O
152	PWE-011â€The psychosocial effects of inflammatory bowel disease on reproductive health – a systematic literature review. , 2018, , .		0
153	PWE-055â€Current smoking trends in british IBD patients in the age of E-cigarettes. , 2018, , .		O
154	PWE-054â€Infliximab therapeutic drug monitoring in IBD virtual biologics clinic leads to durable results. , 2018, , .		0
155	Re: Roberti R, lannone LF, Palleria C, et al. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin. 2020. DOI:10.1080/03007995.2020.1786681. Current Medical Research and Opinion, 2020, 36, 1627-1628.	1.9	0
156	Twitter debate: controversies in pregnancy in IBD and liver disease. Frontline Gastroenterology, 0, , flgastro-2021-101998.	1.8	0
157	Celiac Disease and the Heart. Southern Medical Journal, 2009, 102, 1001-1002.	0.7	O
158	Palliative Treatment of Dysphagia. , 2011, , 193-204.		0
159	Effectiveness and Safety of Vedolizumab (VDZ) in IBD Patients: A Multicenter Experience of "Real World Data―From the U.K American Journal of Gastroenterology, 2017, 112, S381.	0.4	O
160	The UK IBD Registry COVID-19 Risk Tool; Patient Generated Data Can Improve the Hospital Record. SSRN Electronic Journal, 0, , .	0.4	0
161	Letter: potential selection bias in realâ€world comparison of ustekinumab versus vedolizumab as a secondâ€line treatment for Crohn's diseaseâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1070-1071.	, 3.7	O
162	Introduction to the DDS Mini‑Issue: "Inflammatory Bowel Disease and Pregnancy― Digestive Diseases and Sciences, 0, , .	2.3	0